Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-κB activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells

Anti-Cancer Drugs

Volumn 9, Issue 8, 1998, Pages 703-714

  Singh, Sanjaya ^a   Raju, Uma ^a   Mendoza, John ^b   Pantazis, Panayotis ^b   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b St Joseph's Medical Center Houston   (United States)

Author keywords

9 Nitro camptothecin; Cellular resistance; Cytotoxicity; NF B; Tumor necrosis factor

Indexed keywords

DNA TOPOISOMERASE; ENZYME INHIBITOR; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; OKADAIC ACID; PHORBOL ESTER; RUBITECAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; GENE EXPRESSION; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HOST CELL FACTOR C1; HUMANS; HYDROGEN PEROXIDE; I-KAPPA B PROTEINS; INTERLEUKIN-1; LYMPHOMA, LARGE-CELL; NF-KAPPA B; OCTAMER TRANSCRIPTION FACTOR-1; RECEPTORS, TUMOR NECROSIS FACTOR; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031762652     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199809000-00006     Document Type: Article

References (50)

1. Pantazis, P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance and combination treatments. Clin Cancer Res 1995; 1: 1235.
2. Pantazis, P. The water-insoluble camptothecin analogues: promising drugs for the effective treatment of hematological malignancies. Leuk Res 1995; 19: 775-88.
3. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer. Ann NY Acad Sci 1998; in press.
4. Pantazis P, Mendoza JT, DeJesus A, Rubin E, Kufe D, Giovanella BC. Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. Eur J Hematol 1994; 53: 135.
5. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B, Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. Biol Chem 1994; 269: 2433.
6. Pantazis P, Mendoza J, DeJesus A, Early J, Shaw J, Giovanella BC. Development of resistance to 9-nitrocamptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anti-Cancer Drugs 1994; 5: 473.
7. Pantazis P, Vardeman D, Mendoza J, et al. Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leuk Res 19: 43.
8. Nooter, K, Sonneveld P. Clinical relevance of P-glycoprotein expression in hematological malignancies. Leuk Res 1994; 18: 233.
9. Baloch Z, Cohen S, Coffman FD. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J Immunol 1990; 145: 2908.
10. Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Drugs 1998; 9: 36-44.
11. Miyamoto S, Verma IM. REL/NF-κB/IκB story. Adv Cancer Res 1995; 66: 255.
12. Devary Y, Rosette C, DiDonato JA, Karin M. NF-κB activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261: 1442.
13. Anisowicz, A, Messineo M, SW Lee, Sager R. An NF-κB-like transcription factor mediates II-1/TNF-α induction of gro in human flbroblasts. J Immunol 1991; 147: 520.
14. Duyao M P, Buckler AJ, Sonenshein GE. Interaction of an NF-κB-like factor with a site upstream of the c-myc promoter. Proc Natt Acad Sci USA 1990; 87: 4727.
15. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-κB Rel family of transcription factors. Mol Cell Biol 1994; 14: 1039.
16. Wu H, Lozano G. NF-κB activation of p53: a potential mechanism for suppressing cell growth in response to stress. J Biol Chem 1994; 269: 20067.
17. Sarma V, Lin Z, Clark L, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995; 270: 12343.
18. 1 transition in mouse flbroblasts. Mol Cell Biol 1991; 11: 4943.
19. 1 cell cycle arrest but not other inhibitory responses in M1 myeloblastic ceils. Cell Growth Different 1991; 2: 33-41.
20. Duckett GS, Perkins ND, Leung K, Agranoff AB, Nabel GJ. Cytokine induction of nuclear factor κB in cycling and growth-arrested cells. J Biol Cbem 1995; 270: 18836.
21. Schreiber, E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
22. Bradford, MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326: 711.
24. Collart M A, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 1990; 10: 1498.
25. Hassanain HHW, Dai W, Gupta SL. Enhanced gel mobility shift assay for DNA-binding factors. Anal Biochem 1993; 213: 162.
26. Singh H, LeBowitz JH, Baldwin AS, Jr, Sharp PA. Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA. Cell 1988; 52: 415.
27. Chaturvedi M, LaPushin R, Aggarwal BB. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular responses. J Biol Chem 1994; 269: 14575.
28. Singh S, Aggarwal BB. Protein tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-κB. J Biol Cbem 1995; 270: 10631.
29. Higuchi M, Aggarwal BB. Microtiter plate radioreceptor assay for tumor necrosis factor and its receptors in large numbers of samples. Anal Biochem 204: 53.
30. Higuchi M, Aggarwal BB. Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant p60 and p80 receptors. Biochem Biophys Res Commun 1992; 182: 638.
31. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin ASJ. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270: 283.
32. Auphan N, DiDonato JA, Rosette C, Halmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286.
33. Qian J, Bours V, Manischewitz J, Blackburn R, Siebenlist U, Golding H. Chemically selected subclones of the CEM cell line demonstrate resistance to HIV-1 infection resulting from a selective loss of NF-κB DNA binding proteins. J Immunol 1994; 152: 4183.
34. Strum JC, Small GW, Pauig SB, Daniel LW. 1-β-D-arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 1994; 269: 15493.
35. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82: 405.
36. Sun S, Maggirwar SB, Haraj. Activation of NF-κB by phosphatase inhibitors involves the phosphorylation of IκBα at phosphatase 2A-sensitive sites. J Biol Chem 1995; 270: 18347.
37. Suzuki, YJ, Mizuno M, Packer L. Signal transduction for nuclear factor-κB activation: proposed location of anti-oxidants-inducible step. J Immunol 1994; 153: 5008.
38. Schmidt KN, Traenckner EB-M, Meier B, Baeuerle PA. Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-κB. J Biol Chem 1995; 270: 27136.
39. Chan H, Aggarwal BB. Role of tumor necrosis factor receptors in the activation of nuclear factor κB in human histiocytic lymphoma 11-937 cells. J Biol Chem 1994; 269: 31424.
40. Lin K-I, Lee S-H, Narayanan R, Baraban JM, Hardwick JM, Ratan RR. Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. J Cell Biol 1995; 131: 1149.
41. Chaturvedi M, Higuchi M, Aggarwal BB. Effect of tumor necrosis factors, interferons, interleukins and growth factors on the activation of NF-κB: evidence for lack of correlation with cell proliferation. Lymphokine Cytokine Res 1994; 13: 309.
42. Zyad A, Benard J, Tursz T, Clarke R, Chouaib S. Resistance to TNF-α and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD and TNF expression. Cancer Res 54: 825.
43. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism, Science 1988; 242: 941.
44. Kharbanda S, Rubin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-jun protoonco gene in human myeloid leukemia cells. Cancer Res 1991; 51: 6636.
45. Dixit V M, Marks RM, Sarma V, Prochownik EV. The antimitogenic action of tumor necrosis factor is associated with increased AP-1/c-jun proto-oncogene transcription. J Biol Chem 1989; 264: 16905.
46. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989; 245: 371.
47. Bohmann D, Bos TJ, Admon A, Nishimura T, Bogt PK, Tjian R. Human protooncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238: 1386.
48. Anyel P, Allegretto EA, Okino ST, et al. Oncogene jun encodes a sequence specific transactivator similar to AP-1. Nature 1988; 332: 166.
49. Lee YJ, Galaoforo SS, Berns CM, et al Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and nuiltidrug-resistant MCF-7/ ADR cells. J Biol Chem 1995; 270: 28790.
50. Utsugi T, Mattern MR, Mirabelli CK, Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 1990; 50: 2636.